Barbara Neuhaus

Overview
Related items

About Barbara Neuhaus:

No description specified

SEEK ID: https://ldh.zks-mhh.imise.uni-leipzig.de/people/4

Location: Germany

ORCID: https://orcid.org/0009-0002-9485-6602

Joined: 2nd Jun 2025

Expertise: Not specified

Tools: Not specified

help

Their tags

This person has not yet tagged anything.

Related items

Advanced Projects list for this Person with search and filtering

Safety, reactogenicity and immunogenicity of a novel MVA-SARS-2-ST vaccine candidate administered as inhalation boost in SARS-CoV-2 immunized adults – phase I Study

Public web page: Not specified

Start date: 24th Feb 2022

End date: 21st Nov 2023

This is an explorative, open-label, uncontrolled, single center study to explore the preliminary safety, tolerability and efficacy of oral ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency anemia.

Public web page: Not specified

Start date: 27th Mar 2018

End date: 19th Mar 2020

This is an open-label, single arm, multicenter pilot-study to explore the safety, tolerability and efficacy of oral iron supplementation with ferric maltol in treating iron deficiency and anaemia in patients with heart failure.

Public web page: Not specified

A randomized multi-centre double-blind placebo controlled trial to demonstrate theefficacy and safety of nabiximols in the treatment of adults with chronic tic disorders

Public web page: Not specified

Start date: 6th Jun 2025

A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients with chronic heart failure and reduced ejection fraction

Public web page: Not specified

Start date: 23rd Apr 2015

End date: 29th Nov 2024

Advanced Institutions list for this Person with search and filtering

Medizinische Hochschule Hannover

Country: Germany

City: Hannover

Web page: https://www.mhh.de

Showing 5 out of a possible 7 Publications Advanced Publications list for this Person with search and filtering

DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials.

DIGIT-HF

Abstract (Expand)

AIMS: This report presents the baseline characteristics of patients enrolled in the DIGIT-HF trial and compares them with participants from recent trials with improved outcomes in patients with heart …

Authors: U. Bavendiek, N. H. Thomas, D. Berliner, X. Liu, J. Schwab, A. Rieth, L. S. Maier, S. Schallhorn, E. Angelini, S. Soltani, F. Rathje, M. A. Sandu, W. Geller, T. Gaspar, R. Hambrecht, M. Zdravkovic, S. Philipp, D. Kosevic, G. Nickenig, D. Scheiber, S. Winkler, P. M. Becher, P. Lurz, M. Hulsmann, M. von Karpowitz, C. Schroder, B. Neuhaus, A. Seltmann, H. von der Leyen, C. Veltmann, S. Stork, M. Bohm, A. Koch, A. Grosshennig, J. Bauersachs

Date Published: 19th May 2025

Publication Type: Journal

PubMed ID: 40389288

Citation: Eur J Heart Fail. 2025 May 19. doi: 10.1002/ejhf.3679.

Created: 3rd Jun 2025 at 07:33

The DIGIT-HF trial: Key amendments of study design.

DIGIT-HF

Abstract

Not specified

Authors: U. Bavendiek, D. Berliner, N. H. Thomas, X. Liu, J. Schwab, A. Rieth, L. S. Maier, S. Schallhorn, E. Angelini, F. Rathje, M. A. Sandu, W. Geller, T. Gaspar, R. Hambrecht, M. Zdravkovic, S. Philipp, D. Kosevic, G. Nickenig, D. Scheiber, S. Winkler, P. M. Becher, P. Lurz, M. Hulsmann, C. Schroder, A. Seltmann, H. von der Leyen, C. Veltmann, S. Stork, M. Bohm, A. Koch, J. Bauersachs

Date Published: 22nd Jan 2025

Publication Type: Journal

PubMed ID: 39838553

Citation: Eur J Heart Fail. 2025 Mar;27(3):606-608. doi: 10.1002/ejhf.3575. Epub 2025 Jan 21.

Created: 3rd Jun 2025 at 07:28

Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial.

DIGIT-HF

Abstract (Expand)

BACKGROUND: The present study aimed to develop a simple dosing score when starting the cardiac glycoside digitoxin in heart failure with reduced ejection fraction (HFrEF) employing first data from the …

Authors: U. Bavendiek, A. Grosshennig, J. Schwab, D. Berliner, X. Liu, L. Maier, T. Gaspar, A. Rieth, S. Philipp, R. Hambrecht, R. Westenfeld, T. Munzel, S. Winkler, M. Hulsmann, D. Westermann, M. Zdravkovic, R. Lichtinghagen, H. von der Leyen, S. Zimmermann, C. Veltmann, M. Bohm, S. Stork, A. Koch, J. Bauersachs

Date Published: 21st Jul 2023

Publication Type: Journal

PubMed ID: 37087503

Citation: Clin Res Cardiol. 2023 Aug;112(8):1096-1107. doi: 10.1007/s00392-023-02199-z. Epub 2023 Apr 22.

Created: 3rd Jun 2025 at 07:31

Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.

CANNA-TICS

Abstract (Expand)

INTRODUCTION: Gilles de la Tourette syndrome (GTS) is a childhood onset disorder characterised by the presence of motor and vocal tics. The guidelines of both the American Academy of Neurology (AAN) … as well as the European Society for the Study of Tourette Syndrome (ESSTS) recommend behavioural therapy and pharmacotherapy, mainly with antipsychotics, as first line treatments for tics. In spite of these well-established therapeutic approaches, a significant number of patients are dissatisfied because of insufficient tic reduction or intolerable side effects. Previous studies have suggested that cannabis-based medicine (CBM) might be an alternative treatment in these patients. MATERIAL AND METHODS: Two reviewers (KS, NS) searched the electronic database of PubMed on 1 July, 2021 for relevant studies using the search terms: ('Tourette syndrome' [MeSH Terms] OR 'Gilles de la Tourette syndrome' [MeSH Terms] OR 'tic disorders' [MeSH Terms] OR 'tics' [MeSH Terms] OR 'tic disorders'[Title/Abstract]) AND ('cannabis-based medicine' [Title/Abstract] OR 'cannabis' [Title/Abstract] OR 'dronabinol' [Title/Abstract] OR 'nabiximols' [Title/Abstract] OR 'tetrahydrocannabinol' [Title/Abstract] OR 'THC' [Title/Abstract] OR 'cannabidiol' [Title/Abstract], limit: 'humans'. These studies were further reviewed for additional relevant citations. The titles and abstracts of the studies obtained through this search were examined by two reviewers (KS, NS) in order to determine article inclusion. Discrepancies were addressed by the reviewers through discussion and eventually conversation with the senior reviewer (KMV). RESULTS: Although the amount of evidence supporting the use of CBM in GTS is growing, the majority of studies are still limited to case reports, case series, and open uncontrolled studies. To date, only two small randomised controlled trials (RCTs) using tetrahydrocannabinol (THC, dronabinol) have been published demonstrating the safety and efficacy of this intervention in the treatment of tics in patients with GTS. On the other hand, another RCT with Lu AG06466 (formerly known as ABX-1431), a modulator of endocannabinoid neurotransmission, has failed to prove effective in the therapy of GTS. Accordingly, under the guidelines of both the ESSTS and the AAN, treatment with CBM is categorised as an experimental intervention that should be applied to patients who are otherwise treatment-resistant. CONCLUSIONS: Increasing evidence suggests that CBM is efficacious in the treatment of tics and psychiatric comorbidities in patients with GTS. The results of ongoing larger RCTs, such as CANNA-TICS (ClinicalTrials.gov Identifier: NCT03087201), will further clarify the role of CBM in the treatment of patients with GTS.

Authors: N. Szejko, K. Saramak, A. Lombroso, K. Muller-Vahl

Date Published: 29th Oct 2021

Publication Type: Journal

PubMed ID: 34708399

Citation: Neurol Neurochir Pol. 2022;56(1):28-38. doi: 10.5603/PJNNS.a2021.0081. Epub 2021 Oct 28.

Created: 6th Jun 2025 at 13:24

The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders.

CANNA-TICS

Abstract (Expand)

Background: Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterized by motor and vocal tics. First-line treatments for tics are antipsychotics and tic-specific behavioral … therapies. However, due to a lack of trained therapists and adverse events of antipsychotic medication many patients seek alternative treatment options including cannabis. Based on the favorable results obtained from case studies on different cannabis-based medicines as well as two small randomized controlled trials using delta-9-tetrahydrocannabinol (THC), we hypothesize that the cannabis extract nabiximols can be regarded as a promising new and safe treatment strategy in TS. Objective: To test in a double blind randomized clinical trial, whether treatment with the cannabis extract nabiximols is superior to placebo in patients with chronic tic disorders. Patients and Methods: This is a multicenter, randomized, double-blind, placebo controlled, parallel-group, phase IIIb trial, which aims to enroll 96 adult patients with chronic tic disorders (TS or chronic motor tic disorder) across 6 centers throughout Germany. Patients will be randomized with a 2:1 ratio into a nabiximols and a placebo arm. The primary efficacy endpoint is defined as tic reduction of at least 30% (compared to baseline) according to the Total Tic Score of the Yale Global Tic Severity Scale (YGTSS-TTS) after 13 weeks of treatment. In addition, several secondary endpoints will be assessed including changes in different psychiatric comorbidities, quality of life, driving ability, and safety assessments. Discussion: This will be the first large, controlled study investigating efficacy and safety of a cannabis-based medicine in patients with TS. Based on available data using different cannabis-based medicines, we expect not only a reduction of tics, but also an improvement of psychiatric comorbidities. If the cannabis extract nabiximols is proven to be safe and effective, it will be a valuable alternative treatment option. The results of this study will be of high health-economic relevance, because a substantial number of patients uses cannabis (illegally) as self-medication. Conclusion: The CANNA-TICS trial will clarify whether nabiximols is efficacious and safe in the treatment of patients with chronic tic disorders. Clinical Trial Registration: This trial is registered at clinicaltrialsregister.eu (Eudra-CT 2016-000564-42) and clinicaltrials.gov (NCT03087201).

Authors: E. Jakubovski, A. Pisarenko, C. Fremer, M. Haas, M. May, C. Schumacher, C. Schindler, S. Hackl, L. Aguirre Davila, A. Koch, A. Brunnauer, C. L. Cimpianu, B. Lutz, L. Bindila, K. Muller-Vahl

Date Published: 16th Dec 2020

Publication Type: Journal

PubMed ID: 33324255

Citation: Front Psychiatry. 2020 Nov 26;11:575826. doi: 10.3389/fpsyt.2020.575826. eCollection 2020.

Created: 6th Jun 2025 at 13:26

View all 7 Publications

Advanced Documents list for this Person with search and filtering

1 hidden item

(v.1.16.1)

(LDH: v0.3.2)

About NFDI4Health | About Local Data Hub ZKS Hannover | Partners and Funding | Credits | Terms & Conditions | Privacy Policy | Imprint

Copyright © 2008 - 2023 The University of Manchester and HITS gGmbH
Additions copyright ...